SCOPUS 정보 검색 플랫폼

Drug Safety

Volumn 12, Issue 2, 1995, Pages 139-145

A Risk-Benefit Assessment of Risperidone in Schizophrenia

(2) Curtis, Vivienne A a Kerwin, Robert W a

a KING'S COLLEGE LONDON (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; RITANSERIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ABDOMINAL PAIN; AGITATION; ANXIETY; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MALE SEXUAL DYSFUNCTION; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO; VISUAL IMPAIRMENT;

ANTIPSYCHOTIC AGENTS; HUMANS; ISOXAZOLES; PIPERIDINES; RISK; RISPERIDONE; SCHIZOPHRENIA;

EID: 0028968976 PISSN: 01145916 EISSN: 11791942 Source Type: Journal
DOI: 10.2165/00002018-199512020-00006 Document Type: Review

Times cited : (18)

References (43)

1
- 0022447405
- Thymostatic effects of ritanserin (R55667) a centrally acting serotonin (S2) blocker
- 205, 11
- (1986) Drug Dev Res , vol.8
- Reyntjens, A.¹ Gelders, Y.G.² Hoppenbrouwers, M-L³

2
- 0027490544
- Ritanserin a selective 5-HT2/1C antagonist and negative symptoms in schizophrenia. A placebo controlled double blind trial
- 451, 5
- (1993) Br J Psychiatry , vol.163
- Duinkerke, S.J.¹ Botter, P.A.² Jansen, A.A.I.³

3
- 0025572228
- 5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double blind comparison with orphenadrine and placebo
- 500, 6
- (1990) Clin Neuropharmacol , vol.13
- Bersani, G.¹ Grispini, A.² Marini, S.³

4
- 0001485405
- The economic burden of schizophrenia
- 522, 5
- (1990) Psychiatr Bull , vol.14
- Davies, L.M.¹ Drummond, M.F.²

5
- 0023756442
- Biochemical profile of risperidone, a new antipsychotic
- 661, 70
- (1988) J Pharmacol Exp Ther , vol.247
- Leysen, J.E.¹ Gommeren, W.² Fens, A.³

6
- 0023850460
- Pharmacology of risperidone (R64766) a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties
- 685, 93
- (1988) J Pharmacol Exp Ther , vol.244
- Janssen, P.A.J.¹ Neimegeers, C.J.E.² Awouters, F.³

7
- 0027318059
- Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT receptors
- (1993) Psychopharmacology , vol.112 , pp. S40
- Leysen, J.E.¹ Janssen, P.A.J.² Schotte, A.³

8
- 0023688413
- Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol
- 493, 6
- (1988) Psychopharmacology , vol.95
- Megens, A.A.H.P.¹ Awouters, F.H.L.² Neimegeers, C.J.E.³

9
- 84951678653
- D’Aubioul J, Van Gerven W, Wouters L, et al. Cardiovascular and behavioural effects of R64766 (0.08 mg/kg, orally) in conscious dogs, chronically medicated with the compound. Jan 1989. Janssen Preclinical Research Report no.: R64 766/20

10
- 84951678654
- De Coster R, Heyden S, Gelders Y, et al. Effects of single oral and intramuscular administrations of risperidone on plasma prolactin, growth hormone and cortisol levels in healthy male volunteers. Nov 1988. Janssen Clinical Research Report no.: R64 766/14

11
- 84951678655
- Van der Velde V, Gelders Y, Van Rooy, et al. Oral bioavailability and dose proportionality of 0.5, 1 and 2mg risperidone in healthy volunteers. Jul 1987. Janssen Clinical Research Report no.: R64 776/4

12
- 0024462028
- Therapeutic effect and safety of increasing doses of risperidone (R64 766) in psychotic patients
- 445, 9
- (1989) Psychopharmacology , vol.99
- Mesotten, P.¹ Suy, E.² Pietquin, M.³

13
- 85025904130
- Mannens G, Huang M-L, Meuldermans W, et al. Absorption, excretion and metabolism of risperidone in volunteers after a single oral dose of 1mg. Jun 1990. Janssen Clinical Research Report no.: R64 766/25

14
- 85025905097
- Megens A, Neimegeers C. Comparative pharmacology of risperidone, its major metabolite R76 477 (+,−) and the corresponding enantiomers R 78 543 (+) and R 78 544 (−) in rats and dogs. Jun 1990. Janssen Preclinical Research Report no.: R64 766/23

15
- 85025904814
- Steady state tolerance and pharmacokinetics of orally administered risperidone (R64 766) in healthy male volunteers
- Janssen Clinical Research Report, RIS-FRG-9002, Dec
- (1991) A pharmacokinetic report based on revised assay procedures
- Huang, M-L¹ Van Peer, A.² Woestenborghs, R.³

16
- 84951678659
- Huang M-L, Van Peer A, Woestenborghs R, et al. Intravenous pharmacokinetics and absolute bioavailability of risperidone after intramuscular and oral administration in healthy volunteers. Feb 1992. Janssen Clinical Research Report no.: RIS-HOL-9005

17
- 84951678660
- Sack MR. The effects of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Mar 1992. Janssen Clinical Research Report no.: R64 776.JRD0005

18
- 0000503515
- The brief psychiatric rating scale
- (1962) Psychol Res , vol.10 , pp. 799-812
- Overall, J.E.¹ Gorham, D.R.²

19
- 0023606101
- The positive and negative syndrome scale (PANSS) for schizophrenia
- 261, 76
- (1987) Schizophr Bull , vol.13
- Kay, S.R.¹ Fiszbein, A.² Opler, L.A.³

20
- 0004171473
- Univ. of Iowa, Iowa
- (1981) The scale for the assessment of negative symptoms (SANS)
- Andreason, N.C.¹

21
- 84951678661
- Guy W, editor. The Clinical Global Impression. In: ECDEU assessment manual for psychopharmacology, revised. US Department of Health Education and Welfare Publication No. (ADM) Rockville (MD): National Institute of Mental Health, 1976: 36–338

22
- 0000508099
- EPS, a rating scale for extrapyramidal side effects
- 11, 9
- (1970) Acta Psychiatr Scand
- Simpson, G.M.¹ Angus, W.S.²

23
- 0000554506
- Extrapyramidal symptom rating scale
- (1980) Can J Neurol Sci , vol.7 , Issue.3 , pp. 233
- Chouinard, G.¹ Ross-Chouinard, A.² Annable, L.³

24
- 0024474379
- The efficacy of the D2 and 5-HT2 antagonist risperidone (r64 776) in the treatment of chronic psychosis: an open dose finding study
- 411, 5
- (1989) Schizophr Res , vol.2
- Castelao, J.F.¹ Ferreira, L.² Gelders, Y.G.³

25
- 85025892860
- Mesotten J. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double blind study. Aug 1991. Janssen Clinical Research Report no.: RIS-Bel-7

26
- 84951678663
- Borrison R. Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Aug 1991. Janssen Clinical Research Report no.: RIS-USA-9001

27
- 84951678664
- Tatossian A. Comparative double blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophrenia presenting psychotic anxiety symptoms. Nov 1991. Janssen Clinical Research Report no.: RIS-FRA-9003

28
- 85025890831
- Marder SR. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Nov 1991. Janssen Clinical Research Report no.: RIS-INT-3

29
- 85025887692
- Remvig J. Risperidone and perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations: a multicentre double-blind parallel group comparative study. Nov 1991. Janssen Clinical Research Report no.: RIS-INT-7

30
- 85025911932
- Peuskens J. Risperidone in the treatment of chronic schizophrenic patients: an international multi-centre double blind parallel-group comparative study versus haloperidol. Jan 1992. Janssen Clinical Research Report no.: RIS-INT-2

31
- 84951678668
- Mertens C. Risperidone treatment in psychotic patients: a combined analysis of the data from three open long term trials. Feb 1992. Janssen Clinical Research Report no.: RIS-HOL-9002

32
- 0026550602
- Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multi-centre double-blind comparative study
- (1992) Acta Psychiatr Scand , vol.8 S , pp. 295-305
- Claus, A.¹ Bollen, J.² De Cuyper, H.³

33
- 0026741578
- Risperidone: clinical safety and efficacy in schizophrenia
- 213, 8
- (1992) Psychopharmacol Bull , vol.28 , Issue.2
- Borrison, R.L.¹ Pathiraja, A.P.² Diamond, B.I.³

34
- 0027475985
- A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
- (1993) J Clin Psychopharmacol , vol.13 , Issue.1 , pp. 25-40
- Chouinard, G.¹ Jones, B.² Remington, G.³

35
- 0027146306
- Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
- (1993) Acta Psychiatr Scand , vol.88 , pp. 395-402
- Høyberg, O.J.¹ Fensbo, J.² Remvig, J.³

36
- 0028087107
- Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind randomised trial
- 129, 37
- (1994) Prog Neuropsychopharmacol Biol Psychiatry , vol.18
- Heinrich, K.¹ Kleiser, E.² Lehmann, E.³

37
- 0028342655
- Risperidone in the treatment of schizophrenia
- 825, 35
- (1994) Am J Psychiatry , vol.151 , Issue.6
- Marder, S.R.¹ Meibach, R.C.²

38
- 85025889160
- Janssen Pharmaceutica. Chronic toxicity in Wistar rats (repeated dosage for 12 months). Nov 1988. Experiment no. 1788

39
- 84951678670
- Janssen Pharmaceutica Peri and post natal toxicity study in Wistar rats (Segment III). Aug 1987. Experiment no. 2078

40
- 85025893885
- Janssen Foundation
- (1993) Risperidone: investigation brochure

41
- 84951678671
- Janssen Pharmaceutica, Experiment, 1928
- (1991) Oral carcinogenicity study in Wistar rats

42
- 85025891391
- Association of the British Pharmaceutical Industry ABPI, Datapharm Publications, London, April
- (1994) Data sheet compendium 1994–1995

43
- 0027504529
- Overdose of risperidone
- 1908, 10, Dec 22
- (1993) Ann Emerg Med
- Brown, K.¹ Levy, H.² Dranner, C.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.